Bijna 100.000 bezoekers p/mnd! Zie hier
|
29 maart 2007, 16:19 | #61 | |
HaarWeb lid
Geregistreerd: 4 september 2006
Berichten: 984
|
Citaat:
|
|
30 maart 2007, 18:06 | #62 | |
HaarWeb lid
Geregistreerd: 6 maart 2004
Locatie: Ned
Berichten: 941
|
Voor de liefhebber, intercytex heeft wat info over hun phase II op hun site geplaatst:
Citaat:
__________________
AmazingLaserBrush |
|
6 april 2007, 22:00 | #63 |
HaarWeb lid
Geregistreerd: 9 november 2006
Berichten: 4
|
“We are investigating whether there are opportunities to initiate the small scale commercialisation of
ICX-TRC in 2008. This will depend on the outcome of the ongoing Phase II trial and further regulatory review.” Bron: http://www.intercytex.com/icx/news/releases/2007/2007-03-23/2007-03-23.pdf Het bepalen van de waarde die hieraan gehecht dient te worden, laat ik aan eenieder zelf over. |
13 april 2007, 11:52 | #64 |
HaarWeb lid
Geregistreerd: 26 juli 2004
Berichten: 393
|
Intercytex releases FAQ on their ICX-TRC hair cloning procedure
http://news.hairlosshelp.com/hair-cl...ing-procedure/
2010 op de markt. FAQ's zien er veelbelovend uit! Dus nog maar even geen HT dus
__________________
~Accept what you can't change, but change what you can't accept~ 1) minox (gestopt) 2) propecia (gestopt) 3) rozemarijn (gestopt) 4) zorgen over mijn haar (gestopt) 5) tondeuse Wahl pro clip 2000 (gestart!!) 6) headblade! ... Viva La Resistance! |
13 april 2007, 13:31 | #65 |
NW 2-
Geregistreerd: 24 juni 2003
Locatie: Nederland
Berichten: 2.595
|
Follicular Cell Implantation: An Emerging Cell Therapy for Hair Loss by Jeff’ Teumer PhD and Jerry Cooley MD, Seminars in Plastic Surgery/Volume 19, Number 2, 2005
http://www.thieme-connect.com/ejourn.../s-2005-871735 Heeft er iemand hier toegang tot het members-gedeelte? Ik ben wel benieuwd naar de full-text article.
__________________
Regimen: Rogaine foam Minoxidil 5% HW-topical III Multi vit / fibers / DHA+EPA Experimenteel |
25 september 2007, 09:05 | #66 |
NW 2-
Geregistreerd: 24 juni 2003
Locatie: Nederland
Berichten: 2.595
|
Nieuwe press release van intercytex, 25 September 2007.
Voor de volledige press release in PDF formaat, klik hier Intercytex Group plc – Interim results for the six months ended 30 June 2007 25th September 2007 Positive efficacy data emerging across regenerative medicine product portfolio Intercytex Group plc (LSE: ICX), the regenerative medicine company developing innovative products to restore skin and hair, announces its interim results for the six months ended 30 June 2007.Intercytex is a healthcare company developing regenerative medicine products for the woundcare and aesthetic medicine markets. It uses its expertise in cell therapy technology to develop innovative products that harness the innate ability of human cells to regenerate and repair the body. Highlights Products
There will be an analyst meeting to discuss the interim results today at 11am at Financial Dynamics. For those unable to attend, there will be a live audio conference call, the details are as follows. This is a listen only number: Dial in time: 11am Dial in number: 020 7806 1966 Title: Intercytex Slides: http://www.intercytex.com/icx/invest...2007-09-25.pdf If you would like to participate in the question and answer session at the end of the call, please call Claire Rowell on 0207 269 7285 to get the relevant dial in number as it differs from the one above. Enquiries For more information, contact: Intercytex Group plc Nick Higgins, Chief Executive Tel: 0161 904 4500 Richard Moulson, Chief Financial Officer Tel: 0161 904 4500 Financial Dynamics David Yates Tel: 0207 269 7156 Piper Jaffray David Rasouly Tel: 0203 142 8739 Notes for Editors Intercytex is a healthcare company developing regenerative medicine products for the woundcare and aesthetic medicine markets. It uses its expertise in cell therapy technology to develop innovative products that harness the innate ability of human cells to regenerate and repair the body. Intercytex has 4 products in development:
Intercytex commenced operations in 2000 and currently employs around 75 staff. In addition to its head office in Cambridge, UK, it has a GMP clinical production facility with research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, USA. Intercytex' shares trade on AIM, a market of the London Stock Exchange, under the ticker symbol ICX.L. Additional information on the Company can be found at www.intercytex.com Statements contained within this press release may contain forward-looking information or statements with respect to the financial condition, results of operations and business achievements/performance of Intercytex and certain of the plans and objectives of management of Intercytex with respect thereto. By their nature, forward-looking statements involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or similar expressions. A number of factors, including the satisfactory progress of research and development, could cause Intercytex' actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. Forward projections reflect management's best estimates based on information available at the time of issue and are not a guarantee of future performance. Other than as required by applicable law, Intercytex does not undertake any obligation to update or revise any forward-looking information or statements to reflect events or circumstances after the date of this release. The term "Intercytex" refers to Intercytex Group plc and its subsidiary undertakings. View the full press release in PDF format (PDF, 124 KB, opens in a new window). ------------------------ Hair regeneration - ICX-TRC ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells. These cells are able to stimulate the generation of new hairs when injected into the scalp in close proximity to the epithelial cells which generate the hair. The purpose of the ongoing Phase II study being conducted by Dr Bessam Farjo in Manchester is to optimise the delivery of the DP cells. In this study, hair counts are obtained by shaving and photographing a small section of scalp, injecting it and then applying a specialised image analysis system to provide a total hair count. Two sub-groups were each injected with autologous DP cells using different delivery techniques. The first group focussed on delivery of the hair inductive DP cells, and in the second group resident hair producing (epithelial) cells were also stimulated at the time of delivery. Although it is too early to determine fully the differences between the sub-groups, the preliminary data are encouraging. In the first sub-group 2 patients out of 5 showed substantial increases in hair count (21 & 55%) at 24 weeks. In the second sub-group (5 patients in total) injected more recently, all patients showed substantial and visible increased hair counts at 6 and/or 12 weeks (13-105%). We believe this increased hair production is attributable to the interaction between the injected DP cells and the stimulated resident hair producing cells. A further 8 subjects will be treated with variations in delivery technique. The full data set on all subjects at 24 weeks will be available in the middle of 2008. This detailed analysis will form the basis of further Phase II or Phase III trials as appropriate. At the end of the trial photographic data will be analysed from a much larger area of treated scalp on all subjects at 12 months. Currently 2 patients have been lost to follow up.
__________________
Regimen: Rogaine foam Minoxidil 5% HW-topical III Multi vit / fibers / DHA+EPA Experimenteel |
25 september 2007, 10:52 | #67 |
HaarWeb lid
Geregistreerd: 22 september 2006
Berichten: 27
|
Wauw!!! Dat is heel goed nieuws!
Ik heb nog nooit ergens gelezen dat een haircount met 105% is toegenomen binnen 12 weken!! Tevens werkt het ook bij alle proefpersonen, maar niet bij iedereen even goed. Ik vraag me wel af in hoeverre de haren blijven groeien na de behandeling... Zou je ieder half jaar een nieuwe injectie moeten krijgen? Ik kan niet wachten tot dit op de markt komt, vanaf nu ga ik sparen. Misschien is een kleine investering in Intercytex aandelen geen verkeerd idee.
__________________
Intern Finasteride 1,25 mg (vanaf 2007) Extern iGrow laserhelm 4x per week 20 min. (vanaf 2013) Minoxidil 5% 1-2x per dag (08-2007) Regenepure DR en NT (vanaf 03-2013) Laatst gewijzigd door michelangelo; 25 september 2007 om 10:55 |
25 september 2007, 18:04 | #68 |
Moderator
Geregistreerd: 16 maart 2002
Berichten: 25.251
Geslacht: |
Hé bedankt Jaapie.
Ja, dat lijkt heel goed nieuws. |
26 september 2007, 01:49 | #69 |
HaarWeb lid
Geregistreerd: 6 november 2006
Locatie: Amsterdam
Berichten: 2.275
|
Jezus jongens, ik krijg ineens weer echt volle hoop op het idee dat ik mn hele leven gewoon met een kop met een goeie bos haar kan rondlopen .
__________________
Huidig regime: -Ketoconazol (2% shampoo) -Volume shampoo -Finasteride (1,25 mg per dag) Status: NW 3(-) met diffuus uitdunnings patroon in het erfelijk belaste gebied. |
26 september 2007, 11:15 | #70 |
HaarWeb lid
Geregistreerd: 27 december 2003
Berichten: 51
|
Zolang de behandeling nog niet beschikbaar of in ieder geval officieel aangekondigd is moet ik het nog zien, maar inderdaad, het ziet er bijzonder veelbelovend uit! Benieuwd of ze nog proefpersonen zoeken...
|
26 september 2007, 20:00 | #71 |
HaarWeb lid
Geregistreerd: 6 april 2005
Berichten: 2.522
|
Tja, Intercytex moet toch wat doen om de geldschieters tevreden te houden.......
|
27 september 2007, 11:01 | #72 |
NW 2-
Geregistreerd: 24 juni 2003
Locatie: Nederland
Berichten: 2.595
|
pessimist. Luister naar profeet Jaapie, ICX-TRC zal binnen 3 jaar op de markt gebracht worden.
__________________
Regimen: Rogaine foam Minoxidil 5% HW-topical III Multi vit / fibers / DHA+EPA Experimenteel |
27 september 2007, 11:24 | #73 |
HaarWeb lid
Geregistreerd: 27 oktober 2004
Berichten: 32
|
laten we het hopen............die 3 jaar houd men haardos het nog wel uit!!!
|
27 september 2007, 12:18 | #74 |
HaarWeb lid
Geregistreerd: 27 december 2003
Berichten: 51
|
That's the spirit Jaapie!
|
27 september 2007, 18:46 | #75 |
HaarWeb lid
Geregistreerd: 6 april 2005
Berichten: 2.522
|
|
Discussietools | |
Weergave | Geef een waardering voor deze discussie |
|
|
Soortgelijke discussies | ||||
Discussie | Auteur | Forum | Reacties | Laatste bericht |
Wat is de realiteit van Hairmultiplication???? | Henk21 | Overige behandelingen | 78 | 1 maart 2008 11:55 |
Phase 2 hairmultiplication gaat beginnen!! | homersimpson | Overige behandelingen | 33 | 28 december 2006 15:18 |
Hairmultiplication | homersimpson | Overige behandelingen | 36 | 24 september 2006 22:30 |
Hoe ver zijn we met HairMultiplication? | Henk21 | Overige behandelingen | 1 | 6 oktober 2004 12:13 |
Hairmultiplication | Jaapie | Chirurgische behandelingen | 9 | 11 augustus 2003 22:26 |